The cholecystokinin (CCK) receptor is known as a receptor that is overexpressed in many human tumors. The present study was designed to investigate the targeting ability of cyclic CCK analogue in AR42J pancreatic cells. The CCK analogues, DOTA-K(glucose)-Gly-Trp-Nle-Asp-Phe (DOTA-glucose-CCK) and DOTA-Nle-cyclo(Glu-Trp-Nle-Asp-Phe-Lys-NH 2 ) (DOTA-[Nle]-cCCK), were synthesized and radiolabeled with 177 Lu, and competitive binding was evaluated. The binding appearance of synthesized peptide with AR42J cells was evaluated by confocal microscopy. And bio-distribution was performed in AR42J xenografted mice. Synthesized peptides were prepared by a solid phase synthesis method, and their purity was over 98%. DOTA is the chelating agent for 177 Lu-labeling, in which the peptides were radiolabeled with 177 Lu by a high radiolabeling yield. A competitive displacement of 125 I-CCK8 on the AR42J cells revealed that the 50% inhibitory concentration value (IC 50 ) was 12.3 nM of DOTA-glucose-CCK and 1.7 nM of DOTA-[Nle]-cCCK. Radio-labeled peptides were accumulated in AR42J tumor in vivo, and %ID/g of the tumor was 0.4 and 0.9 at 2 h p.i. It was concluded that 177 Lu-DOTA-[Nle]-cCCK has higher binding affinity than 177 Lu-DOTA-glucose-CCK and can be a potential candidate as a targeting modality for a CCK receptor over-expressing tumors.
Introduction
Several receptors are overexpressed in specific tumors (1) . The CCK receptor is known as a G-protein-coupled receptor (GPCR) that was first discriminated pharmacologically by the differential affinities of gastrin and CCK. It is overexpressed in various cancer cells. And its incidence is higher than other cancer in the lung and pancreatic cancer (2, 3) . The affinity of gastrin is a requirement to distinguish CCK receptor subtype (4) . The affinity level of gastrin with a CCK1 receptor is low, but the affinity level of gastrin with a CCK2 receptor is higher than the affinity level with CCK1 receptor. In receptor binding progress, Tyr residues of the peptide have a critical function in the specificity of receptor (5) . If this residue is sulfated, the peptide shows a high affinity for CCK1 and CCK2 receptors. This is displayed in small cell lung cancer rich in CCK2 receptors. However, despite the studies of CCK2 receptor expression on several cancer cell, no methods are not approved for use this receptor in the radiopharmaceutical development (6) .
The targeting moiety of the CCK peptide is shown in C-terminal amino acid sequences Trp-Met-Asp-Phe-NH 2 for maintaining the binding affinity of receptor and preserving the CCK-like peptides biological activity (7) . Hence, the peptide N-terminal region may be used for labeling with radioisotopes and a number of influential CCK analogues have been labeled with many radioisotopes such as 177 Lu, 68 Ga, 99m Tc, 111 In, 90 Y, 18 F or 64 Cu for targeting CCK receptorexpressing cancer cells (8) .
Among the available radionuclides, 177 Lu decays by a half-life of 6.7 days with the emission of beta-rays (497 keV) and gamma-rays (208 keV), and it is a fantastic therapeutic radionuclide with great potential for peptide receptor radionuclide therapy (9) . Thus, 177 Lu can check the injected therapeutic radiopharmaceuticals localization in body during treatment. The well-known chelating agent of radiolabeling peptides with 177 Lu is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (10) . 177 Lu presents primarily in 3 þ oxidation state and is stabilized by nitrogen or oxygen.
In this study, we employed cyclic CCK2 as a linker of DOTA to prepare radiolabeled candidates for CCK receptor targeting. DOTA-[Nle]-cCCK was synthesized and radiolabeled, and IC 50 of the peptides by 125 I-CCK8 on human pancreatic tumor cells were evaluated.
Materials and methods

Cell culture
AR42J pancreatic carcinoma cells were purchased from the ATCC (American Type Culture Collection) and cultured in RPMI-1640 (LONZA, Walkersville, MD, USA), supplemented with 100 units/ mL penicillin, 100 g/mL streptomycin, and 10% fetal bovine serum (Sigma, Milan, Italy) in 100 mm dishes. Also, the AR42J pancreatic carcinoma cells were cultured in 5% CO 2 atmosphere in air at 37 C for up to about 90% confluence (11).
Peptides
The DOTA-[Nle]-cCCK and DOTA-glucose-CCK were synthesized through the automated Multiple Biomolecular Synthesizing System by Peptron ® (Daejeon, South Korea). Fmoc-amino acid conjugated 4-Methylbenzhydrylamine (MBHA) resin was used as an anchor polymeric support for a solid phase synthesis. After removing the Fmoc protecting group from resin bounded Fmoc-Met-OH under a standard cleavage condition (20% Piperidine in N,N-Dimethylformamide). The resulting peptides were cleaved from the polymeric support by treatment with a mixture solvent of 90% TFA containing 2.5% Triisopropylsilane (TIS), 2.5% Ethanedithiol (EDT), 2.5% thioanisole and 2.5% deionized water (TFA:TIS: EDT:Thioanisole:H 2 O ¼ 90:2.5:2.5:2.5:2.5). The crude products were purified using a Shimadzu HPLC equipped with a Capcell pak C18 column on a binary gradient system at a flow rate of 1.0 mL min À1 using an elution solvent of 0.1% Trifluoroacetic Acid (TFA) in water (A) and 0.1% TFA in acetonitrile (B) with a gradient elution profile of (B): 0e10% in 2 min; 10e40% in 10 min; and 40e70% in 2 min. The molecular mass was analyzed on an LC-MS ( Fig. 1 ).
Radiolabeling
CCK2 analogues were liquefied in a sodium acetate buffer (50 mM, pH 5.5) to give a 10 À6 mol/mL. The diluted 177 LuCl 3 solution (37 MBq) in a 5.5 M HCl was injected into a vial of the peptide (10 À8 mol) solution to give a final volume of 1 mL. And this vial was heated at 90 C for 30 min. The yield of radio-labeling, the radiochemical purity of the radiolabeled compound, and the stability of the radiolabeled compound were analyzed by a Waters Chromatograph equipped with an X-Terra C-18 column. The column was eluted with a binary gradient system with a flow rate of 1.0 mL/min using an elution solvent of 0.1% TFA and 5% acetonitrile in water and 0.1% TFA and 5% water in acetonitrile. The gradient elution profile based on the solution of 0.1% TFA and 5% water in acetonitrile is as follows: 0%, 5 min; 0e100%, 9 min; 100%, 6 min; 100%, and 2 min with 100% of 0.1% TFA and 5% acetonitrile in water.
Receptor binding study
The receptor binding in vitro of the peptides labeled with 177 Lu were investigated on AR42J cells. AR42J cells were cultured in 12well plates and incubated with 125 I-CCK8 (Perkin Elmer, 370 kBq, 800e10,000 cpm) in a binding buffer. After incubation at room temperature for 60 min, the cells were washed for three times with PBS and counted using a gamma-counter to determine the cell associated radioactivity.
IC 50 determination
The 50% inhibitory concentration (IC 50 ) for binding affinity of CCK analogues on CCKR was investigated on AR42J cells by a competitive binding assay. AR42J cells were incubated in 12-well plates. Grown AR42J cells were washed for three times with a binding buffer. A range of 10 À12 to 10 À6 M unlabeled peptides were added with a trace amount of 125 I-CCK8 (10,000 cpm/mL) after 15 min incubation at room. The medium was collected and wash the cells for three times with PBS after incubation at room temperature for 60 min. The cells were solubilized with 1 N NaOH for 10 min. Gamma-counter was used to determine the radioactivity of cells. GraphPad Prism software was used to calculate the IC 50 values (Version 5.00 for Windows).
Immunofluorescent confocal microscopy
For the assay of binding moiety of DOTA-[Nle]-cCCK with CCKR, AR42J cells were cultured in a coverglass-bottom dish.
AR42J cells were treated with 10 mL of DyLight 633 NHS Ester (Thermo Scientific, Hudson, NH, USA)-conjugated DOTA-[Nle]-cCCK for 20 min and a propidium iodide was added for nucleus detecting. The cells were fixed with 4% CH 2 O and 3% sucrose for 20 min. The cells were stained for 2 h with a rabbit polyclonal anti-CCKR antibody and then incubated for 1 h with Alexa Fluor 488 conjugated secondary antibodies. Confocal microscopy is used to observe the stained cells.
Biodistribution assay
Six weeks of age male BALB/c nude mice were supplied from Nara Biotec, Inc. (Seoul, Korea). All mice were housed in wire cages at 23 ± 2 C and 50 ± 5% humidity, fed standard laboratory chow (Samyang, Seoul, South Korea), and allowed water ad libitum. All of procedures relating to the animals and their care conformed to the Institutional Animal Care and Use Committee at KAERI approved the protocols and the Guidelines for Animal Experiments.
For AR42J xenograft mice model, harvested AR42J cells (10 6 cells/mouse) were subcutaneously injected in the left upper flank. After inoculation for 7 days, the tumors were developed to ranging in mass from 0.11 ± 0.082 g. After tail vein injection with 370 kBq of the 177 Lu-DOTA-glucose-CCK and 177 Lu-DOTA-[Nle]-cCCK in 100 mL of saline, the study of biodistribution was performed in AR42J xenograft mice. After injection for 2 h, all mice were sacrificed using CO 2 , and each tissue sample was collected. Blood samples were collected using cardiac puncture. The tissue of tumor and normal organs (liver, kidney, spleen, heart, small intestine, large intestine, lung, and stomach) were excised, weighed, and counted using a gamma counter. The organ uptake was calculated as a percentage of the injected dose per gram of organ tissue (%ID/g). For the experiment using blocking agent, mice were injected with a cold peptide (10 À8 mol). And after injection for 2 h, a bio-distribution experiment with blocking agent was performed.
Statistical analysis
All values are expressed as mean ± standard deviation (SD) with statistical significance analyzed using a Welch's corrected unpaired Student's t test or one-way analysis of variance using a GraphPad Prism computer fitting program.
All data are expressed as the mean ± standard deviation with statistical significance analyzed using one-way ANOVA followed by a StudenteNewmaneKeuls test. 
Results
Nonradioactive peptides were synthesized by solid phase peptide synthesis following the standard Fmoc strategies. The final peptide sequence of DOTA-glucose-CCK was DOTA-K(glucose)-Gly-Trp-Nle-Asp-Phe, and DOTA-[Nle]-cCCK was DOTA-Nle-Cyclo(Glu-Trp-Nle-Asp-Phe-Lys-NH 2 ).
The new conjugates, 177 Lu-DOTA-glucose-CCK and 177 Lu-DOTA-[Nle]-cCCK, were routinely prepared in a high yield (>98%) by adding 177 LuCl 3 to an aqueous solution (pH 5.5 ammonium acetate) of the peptides at 90 C for 30 min. The HPLC chromatogram of 177 Lu-DOTA-glucose-CCK and 177 Lu-DOTA-[Nle]-cCCK showed a retention time of 12.12 min and 12.29 min, respectively (Fig. 2) .
The in vitro CCK receptor binding affinities and specificities of DOTA-glucose-CCK and DOTA-[Nle]-cCCK were assessed through a competitive displacement assay using 125 I-CCK8 as the radiopeptide ( Fig. 3) . It was found that DOTA-glucose-CCK and DOTA-[Nle]-cCCK were able to compete with 125 I-CCK8 bound to AR42J pancreatic carcinoma cells. In another peptide of CCK, the IC 50 value of DOTA-sCCK8, sulfated cholecystokinin fragment 26e33, is 10.6 nM. However, IC 50 values of new cyclic peptides were 11.93 nM and 1.57 nM for DOTA-glucose-CCK and DOTA-[Nle]-cCCK, respectively. It seems that the structure using Nle instead of Met in a CCK analogue has a higher binding affinity than the original CCK analogue in cyclic structures.
We examined whether cyclic peptide binds with CCKR in AR42J cells using a confocal microscopy analysis. According to a confocal microscope analysis, the fluorescence intensity of DOTA-[Nle]-cCCK as well as CCKR was observed in the cell membrane (Fig. 4) .
The results of the bio-distribution assay of the 177 Lu-labeled CCK peptides in AR42J pancreas tumor xenografted mice are shown in Fig. 5 . They were compared to a group administered non-labeled peptide (cold peptide). The 177 Lu-labeled CCK analogues also cleared efficiently from the bloodstream, with 0.41 ± 0.03% and 0.7 ± 0.01% ID/g remaining at 2 h p.i. The radio labeled cyclic peptides were accumulated in the tumors at 2 h p.i. (0.4 and 0.9% ID/g). In a blocking study, the tumor uptake was reduced by a coinjection of excess cold-peptide.
Discussion
The research of cancer treatment is in progress in many fields, and many researchers have been interested in radioimmunotherapy (RIT). In various fields of research, because of the physical properties of radiation, a radiation emitted by radioisotopes has been investigated for medically using (12, 13) . Based on this background, the interest of theranostic compounds is increasing. Patients are selected by the diagnostic study to determine whether a person to be treated. After 131 I is used for diagnostic imaging and therapy, the studies of theranostic radioisotopes have been in progress and many studies are being conducted for 177 Lu.
The apoptotic effect of radiation emitted by injected radioisotopes must be accumulated into a high portion of tumor tissues to treat cancer, and it is important to find a way of targeting (14) . To increase the efficiency of the receptor targeting, there are two elements, i.e., the binding affinity with a specific receptor and the material stability (15e17). If the binding ability of the receptor becomes higher, the ability to deliver the labeled radioisotope to specific cancer cells becomes excellent. In addition, increasing the stability of the substance administered increases the binding affinity with the receptor on the cancer cells owing to the reduction in the material deformation and degradation (10) .
To increase the affinity of the injected material with the receptor, it is mainly being studied to transform a portion of a known ligand structure (18) . To increase the binding affinity of the drug conjugate with cancer cells, ligands, binding with selective receptor on cancer cells, and modified research have been studied. If the binding affinity with a receptor is higher than the conventional ligand, it can be used to transport a radioisotope to cancer cells. To increase the stability of injection peptides, various methods have been studied. In variety of ways, the cyclization of the peptide was conducted to enhance the stability of melanoma targeting peptide (19e21).
In this study, we synthesize the targeting materials of the cholecystokinin (CCK) receptor. The CCK receptor is known as a receptor that is overexpressed in various tumor cells. Its incidence is especially higher in lung and pancreatic cancers than other cancers. Studies on tumor-associated through CCK peptides are actively performed. However, improved binding affinity with CCKR in cancer tissue has emerged through research.
Several methods have been studied to improve the binding affinity of the CCK analogues with CCKR in tissue. The glucose attached to the side chain of Lys was introduced to the N-terminal region of the CCK targeting moiety to decrease the lipophilicity of the peptide. Decreasing the lipophilicity of the CCK analogue may lead to derivatives with improved sensitivity, specificity, and pharmacokinetics for the optimal targeting of CCKR-expressing tumors. There is another way to improve the reliability through the cyclization of the peptide. The blood stability of cyclized peptide has been demonstrated in studies on the target peptide of pancreas and melanoma. High stability is connected with high effectiveness. Actually, the binding affinities of the cyclic structure CCK peptides were higher than the linear structure CCK peptides.
Bifunctional chelating agents (BFCA) are used for the preparation of many radiolabeled compounds. In particular, DOTA is able to strongly chelate many radionuclides such as 177 Lu, 111 In, 149 Pm, 212 Pb, 90 Y, and 68 Ga. Additionally, 177 Lu emits strong energy b-rays (497 keV) and g-rays (208 keV), and its half life is short (6.67 day). Thus, 177 Lu is considered a suitable radionuclide for performing therapy with the imaging of tumors or metastatic deposits. DOTA-glucose-CCK and DOTA-[Nle]-cCCK were also easily labeled with 177 Lu.
In the previous report, the stability of radioisotope labeled DOTA-[Nle]-cCCK is higher (>98%) than non-cyclic peptide in blood. In addition, the binding affinity of cyclic CCK analogue was better than non-cyclic peptide analogue (11) .
In accordance with the results, DOTA-[Nle]-cCCK showed a higher binding affinity than DOTA-glucose-CCK on the CCK receptor. In addition, the in vivo tumor accumulation rate of 177 Lu-DOTA-[Nle]-cCCK is higher than 177 Lu-DOTA-glucose-CCK in the AR42J injected mice xenograft model.
The kidney is the major excretion organ for i.v. injected radiolabeled peptides, and an improved tumor-to-kidney ratio is important to decrease the toxicity of radio peptide. Although a lot of injected 177 Lu labeled CCK peptides uptake in the kidney, they showed a lower uptake and retention in the liver. Because of this, they can be a high in vivo stability. These results are united with the previously reported in vitro CCK peptide stability (11) .
If DOTA-[Nle]-cCCK is applied to the clinical approach, lung cancer patients would be diagnosed by SPECT-CT using 177 Lu-DOTA-[Nle]-cCCK after taking a biopsy for the evaluation of CCK receptor expression. In addition, the diagnosis of lung cancer can be confirmed, and the tumor burden including metastases can also be assessed using 177 Lu-DOTA-[Nle]-cCCK for functional imaging. Next, the patients would begin the treatment using high dose of 177 Lu-DOTA-[Nle]-cCCK, and the absorbed dose to the tumor and the toxicities to normal organs would be evaluated by SPECT-CT, which can make prognosis predictions.
Therefore, the pharmacokinetic characteristics and therapeutic efficacy of 177 Lu-DOTA-[Nle]-cCCK should be evaluated in the next investigation. If 177 Lu-DOTA-[Nle]-cCCK shows fast excretion in the kidneys, it can be expected to be a good pharmaceutical agent in further in vivo studies.
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